Innavac is a biotechnology company seeking to transform the treatment and prevention of respiratory infections and the effectiveness of vaccines. Innavac’s R&D activities are undertaken partly through a collaboration between Innavac’s founding scientist, Professor David Jackson at the Department of Immunology of the University of Melbourne (Peter Doherty Institute for Infection and Immunity), and Dr Nathan Bartlett at the Hunter Medical Research Institute.

For more information visit: